News summary

Amprion, Prema Cognition build accessible pathway for early neurodegenerative disease detection

Source: Longevity Technology • Published: 02 Oct 2026, 09:36

Summarized by Masters of Longevity from Longevity Technology.

A news piece about a new collaborative pathway combining a quick digital memory check with lab biomarker confirmation for earlier neurodegenerative assessment, inviting readers to learn how the approach could streamline screening and research.

Amprion, Prema Cognition build accessible pathway for early neurodegenerative disease detection
Key Takeaways
  • Prema Cognition's PREMAZ is a 10–15 minute digital precision memory test developed with the University of Cambridge Memory Lab.
  • Amprion's seed amplification assay SAAmplify-αSYN received FDA Breakthrough Device designation in 2019 and launched commercially in the United States in 2021.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.